$LMMY completes acquisition of cancer therapy innovator Exousia AI and secures Orphan Drug Designation for its Glioblastoma therapy. Major preclinical wins and exclusive exosome tech set the stage for rapid growth. Read the PR:
https://globenewswire.com/news-release/2025/1...I-Inc.html